Natera (NTRA) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 revenue of $439.8M, up 64% year-over-year, with total test volumes up 24% to approximately 776,000 and oncology test volumes up 54%.

• Gross margin improved to 62% in Q3 2024 from 45.1% in Q3 2023, driven by higher ASPs and cost efficiencies.

• Net loss narrowed to $31.6M ($0.26/share) from $109.0M ($0.95/share) in Q3 2023, with positive cash flow of $34.5M in Q3 2024.

• Major clinical milestones included publication of the GALAXY study in Nature Medicine and completion of the CALGB/SWOG 80702 trial analysis.

• All outstanding convertible senior notes were redeemed or converted in October 2024, leaving the company effectively debt-free.

Financial highlights

• Q3 2024 revenue was $439.8M, a 64% increase year-over-year; product revenues reached $436.1M, and oncology test volumes hit 137,000, up 54%.

• Gross margin reached 62% in Q3 2024, up from 45.1% in Q3 2023, driven by product mix and ASP improvements.

• Cash and investments totaled $922.3M as of September 30, 2024, with positive cash flow of $34.5M in Q3.

• Net loss per diluted share improved to ($0.26) from ($0.95) in Q3 2023.

• Loss per share narrowed significantly as scale and margin expansion offset increased OpEx.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $1.61B–$1.64B, with gross margin expected at 58%–61% and net cash inflow projected at $50M–$75M.

• SG&A costs expected at $775M–$825M and R&D at $375M–$400M for 2024.

• Organic revenue (excluding true-ups) for 2024 expected at $1.51B–$1.54B, with gross margins of 56%–58%.

• Baseline 2025 goal is to match 2024 unit growth, with some expected ASP stability and potential modest improvement for Signatera.

• Existing cash and marketable securities expected to meet anticipated cash requirements for at least 12 months after November 12, 2024.